雷珠单抗治疗伴或不伴视网膜前出血的ROP的疗效观察

目的:对比研究玻璃体腔注射雷珠单抗治疗伴或不伴视网膜前出血(PRH)的早产儿视网膜病变(ROP)的疗效。方法:收集2017-04/2018-01在本院行玻璃体腔注射雷珠单抗治疗的ROP患儿34例66眼进行回顾性分析研究。将所有患儿按照有无PRH分成两组:ROP伴PRH组26眼与ROP不伴PRH组40眼。所有患儿均在表面麻醉下行玻璃体腔注射雷珠单抗,对患儿术后情况进行观察,分析两组患儿的一次治愈及需要二次治疗情况。结果:经过首次玻璃体腔注射雷珠单抗治疗后随访至12mo,ROP伴PRH组和ROP不伴PRH组患儿一次治愈构成比分别为65%(17眼)和98%(39眼),需要二次治疗的构成比分别为35%(9眼)和2%(1眼)。需要二次治疗病例经过二次玻璃体腔注射雷珠单抗药物治疗,均全部治愈。两组间的一次治愈构成比有差异(P<0.05)。结论:玻璃体腔注射雷珠单抗治疗伴PRH的ROP的一次治愈效果明显低于不伴PRH的ROP的患儿,需要二次治疗病例经过再次玻璃体腔注射雷珠单抗治疗可以得到治愈。

Clinical observation of Ranibizumab on retinopathy of prematurity with or without preretinal hemorrhage

AIM: To compare the therapeutic effect of Ranibizumab on retinopathy of prematurity(ROP)with or without preretinal hemorrhage(PRH).

METHODS: From April 2017 to January 2018, a retrospective study was carried out on the diagnosed and treated ROP cases 66 eyes of 34 in the Affiliated Eye Hospital of Nanchang University. All the infants were divided into two groups according to PRH or not. All patients were treated with intravitreal Ranibizumab under tropical anesthesia. The infants were followed up, and the cure and retreatment rate between the two groups after initial treatment were compared.

RESULTS: After the initial treatment of intravitreal Ranibizumab, the cure rate was 65%(17)and 98%(39), and the retreatment rate was 35%(9)and 2%(1)in bleeding and non-bleeding group, respectively. 9 eyes with PRH needed retreatment; however, only 1 eye retreatment in the non-bleeding group. Notably, all the retreatment cases were cured by once more intravitreal Ranibizumab. The cure rate between two groups was statistically significant.

CONCLUSION: The curative effect with initial treatment of ROP with PRH was significantly lower than that without PRH. The retreatment cases were attenuated by repeated intravitreal Ranibizumab treatment.